Design Therapeutics (DSGN) Current Assets (2020 - 2026)

Design Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $227.0 million for Q1 2026.

• In Q1 2026, Current Assets fell 2.82% year-over-year to $227.0 million; the TTM figure through Mar 2026 stood at $227.0 million (down 2.82% YoY), while the FY2025 annual figure was $223.8 million, down 9.78% from the prior year.
• Current Assets came in at $227.0 million for Q1 2026 at Design Therapeutics, up from $223.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $373.9 million in Q1 2022 to a low of $209.0 million in Q3 2025.
• A 5-year average of $281.2 million and a median of $273.9 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slipped 18.74% in 2025 and retreated 2.82% in 2026, its largest moves.
• Design Therapeutics' Current Assets stood at $335.1 million in 2022, then declined by 15.08% to $284.6 million in 2023, then fell by 12.84% to $248.0 million in 2024, then slipped by 9.78% to $223.8 million in 2025, then gained by 1.46% to $227.0 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $227.0 million, $223.8 million, and $209.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison